arrow
P

Paolo Vigneri

University of Catania
H指数:48
被引数:8,903

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Risk stratification and relapse pattern in triple-negative breast cancer with pathological complete response after neoadjuvant treatment: the European GAMBIT real-world study
2026-06-240
OAAI
Preclinical Rationale, Clinical Efficacy, and Safety of the Selective AKT Kinase Inhibitor Capivasertib in Metastatic Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Carcinoma: A Practical Narrative Review

临床前理论依据、临床疗效及选择性AKT激酶抑制剂Capivasertib在转移性激素受体阳性、人表皮生长因子受体2阴性乳腺癌中的安全性:一项实用性叙事综述

2026-04-040
OAAI
Targeting leukemic stem and progenitor cells expressing different BCR::ABL1 levels: antileukemic activity of asciminib with or without TKIs

靶向表达不同BCR::ABL1水平的白血病干细胞和祖细胞:asciminib单独或联合TKIs的抗白血病活性

2026-03-300
OAAI
Comprehensive review of pregnancy associated breast cancer: clinical features, molecular characteristics and novel therapies

妊娠相关性乳腺癌的全面综述:临床特征、分子特征及新型疗法

2026-01-120
PRE
Association of Neoadjuvant Chemotherapy Dose Intensity with Pathological Complete Response and Event-Free Survival in HER2-Negative Early Breast Cancer

新辅助化疗剂量强度与HER2阴性早期乳腺癌病理完全缓解及无事件生存期的关系

2025-11-120
PRE
RSC4All as a machine learning nomogram to predict RSClin™ results in HR+/HER2- node-negative early breast cancer

RSC4All 作为一种机器学习列线图,用于预测 HR+/HER2- 淋巴结阴性早期乳腺癌的 RSClin™ 结果

2025-10-070
OAAI
Unlocking the Potential of Immune Checkpoint Inhibitors in HR+/HER2− Breast Cancer: A Systematic Review

解锁免疫检查点抑制剂在HR+/HER2−乳腺癌中的潜力:一项系统综述

2025-09-230
OAAI
Predictors of mastectomy in breast cancer patients with complete remission of primary tumor after neoadjuvant therapy: A retrospective study

新辅助治疗后原发肿瘤完全缓解的乳腺癌患者行乳房切除术的预测因素: 一项回顾性研究

EJSO
IF2.9
2024-12-0110
OAAI
Bridging the gap between real-world studies (RWSs) and randomized controlled trials (RCTs) of 1st-line palbociclib plus aromatase inhibitors (P plus AI) in hormone receptor-positive (HR+)/HER2-negative(-) metastatic breast cancer (mBC)

弥合真实世界研究(RWSs)与1线帕博西利联合芳香化酶抑制剂(P plus AI)在激素受体阳性(HR+)/人表皮生长因子受体2阴性(-)转移性乳腺癌(mBC)中的随机对照试验(RCTs)之间的差距

2024-09-010
PRE
Comparison of video-assisted pleurectomy/decortication surgery plus hyperthermic intrathoracic chemotherapy with VATS talc pleurodesis for the treatment of malignant pleural mesothelioma: A pilot study

视频辅助胸膜切除/剥脱术加胸腔热化疗与VATS滑石粉胸膜固定术治疗恶性胸膜间皮瘤的比较: 一项初步研究

HELIYON
IF3.6
2023-06-019
OAAI